Science1 publisher2 min readPublished
Stem cell industry bets the FDA's peptide opening will let it in next
Stem cell entrepreneur Chuck Meeker predicts a series of FDA roundtables on his industry's therapies before the end of the year. The agency declined to say whether any are planned, so for now the forecast tells us more about what the industry hopes than about what the FDA intends.
The Scientist · Science desk
Drafted by a language model from the sources cited here and checked against its claim ledger before publication. How we use AISend a correction
What happened
- Compounded peptides have won a tentative welcome at the FDA, while commercially sold, unapproved stem cell therapies remain out of favour with the agency.
- Others at the PepMed conference told STAT they share Meeker's belief that the agency's stance on stem cells is about to change.
- The industry sees the peptide opening as its chance to move stem cell products out of the grey market and to millions of Americans.
- According to STAT, these advocates think RFK Jr. could put stem cells on the same path peptides have taken with the agency.
Compiled by The ScientistSomething wrong?How this is made
Why it matters
- constraint A roundtable can put stem cells on the FDA's agenda, but any evidence-based route out of the grey market still needs controlled data on how much these treatments help.
- exposure The industry's stated target is millions of Americans, so an FDA that treats stem cells the way it now treats peptides would widen patient access to products it has not approved.
- decision The FDA has to decide whether its softer line on compounded peptides is a one-off or a template, and stem cell sellers are already treating it as a template.
Meeker hedged the forecast himself. "If I were a betting man, I would say before the end of the year we have a series of FDA roundtables happening," he told STAT [2]. He made the prediction at PepMed 2026, the American Academy of Peptide Medicine's meeting for companies in the regenerative health business [3].
Opinion collected at a trade meeting tells you about the people who attended it. At PepMed those people run regenerative health businesses [3]. Their expectation of a friendlier FDA reflects their own hopes at least as much as anything the agency has signalled. In my view the useful part of Meeker's claim is the deadline, because it can be checked against the agency's calendar by the end of the year [2].
STAT puts peptides and stem cells together under regenerative medicine, a field it describes as focused on therapies that claim to trigger the body's natural healing mechanisms [5]. I would ask any such therapy the usual questions: how many patients were treated, compared against what control group, and how large the benefit was. The reporting does not answer them for the stem cell products at issue.
A roundtable would not answer them either. It is a public discussion. It can put stem cells on the agency's agenda without producing a single measured effect. The industry's case for holding that discussion rests on the peptide precedent [8]. That precedent is about how the FDA has behaved, and it says little about the products themselves. Whether unapproved stem cell products have evidence comparable to compounded peptides is a separate question.
What to watch
- Whether the FDA schedules any stem cell roundtables before the end of the year, the deadline Meeker set.
- Any FDA statement that separates its approach to compounded peptides from its approach to unapproved stem cell therapies.
- Whether advocates bring controlled clinical data, with patient counts and effect sizes, to any meeting the agency does hold.